Business
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025
WILMINGTON, Del., April 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"WILMINGTON, Del., April 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\", or the \"Company\"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., (\"HOPE,\" or the \"Company\"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that it will participate in an H.C. Wainwright @ Home fireside discussion, taking place on Tuesday, April 22, 2025 at 10AM EDT.\n\n \n \n \n \n \n \n\n \nJonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals, and Co-CEO of HOPE Therapeutics, will participate in a fireside chat lead by HCW Senior Biotech Analyst, Vernon Bernardino.\nEvent Details:\nEvent: HCW @ Home with NRx Pharmaceuticals, Inc. (NRXP)Date: Tuesday, April 22nd, 2025, 10:00 AM EDTWebcast: https://ir.nrxpharma.com/eventsInvestors interested in watching the event can use the link above or contact their HC Wainwright representative to register. \nAbout NRx Pharmaceuticals, Inc.\nNRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.\nNRx recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.\nAbout HOPE Therapeutics, Inc.\nHOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network ...